New Insights into the Occurrence of Matrix Metalloproteases -2 and -9 in a Cohort of Breast Cancer Patients and Proteomic Correlations

Cara, Gianluca Di; Marabeti, Maria Rita; Musso, Rosa; I, Riili; Pucci‐Minafra, Ida

doi:10.20944/preprints201806.0145.v1

Cited by 4 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matrix metalloproteases (MMPs) are a family of enzymes that differ in their structure, substrate specificity, sequence homology, cellular localization and secretion. For this reason, they are divided into different subfamilies: collagenases, gelatinases, matrilysins, stromelysins, membrane type MMPs and others MMPs . MMPs are mainly involved in extracellular matrix (ECM) remodelling, but they are also capable of processing proteins unrelated to the ECM and activating other MMPs and proteases .…”

Section: Introductionmentioning

confidence: 99%

“…For this reason, they are divided into different subfamilies: collagenases, gelatinases, matrilysins, stromelysins, membrane type MMPs and others MMPs . MMPs are mainly involved in extracellular matrix (ECM) remodelling, but they are also capable of processing proteins unrelated to the ECM and activating other MMPs and proteases . MMPs are key regulators of cell‐cell interactions and perform different functions in a variety of normal biological and carcinogenic processes (tumour growth, angiogenesis, degradation of collagen in basal membrane, changes in the epithelial‐mesenchymal transition [EMT], invasion and metastasis) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study

Olivares-Urbano

Griñán‐Lisón

Zurita

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Breast cancer (BC) is the most common tumour in women and one of the most important causes of cancer death worldwide. Radiation therapy (RT) is widely used for BC treatment. Some proteins have been identified as prognostic factors for BC (Ki67, p53, E‐cadherin, HER2). In the last years, it has been shown that variations in the expression of MMPs and TIMPs may contribute to the development of BC. The aim of this pilot work was to study the effects of RT on different MMPs (‐1, ‐2, ‐3, ‐7, ‐8, ‐9, ‐10, ‐12 and ‐13) and TIMPs (‐1 to ‐4), as well as their relationship with other variables related to patient characteristics and tumour biology. A group of 20 BC patients treated with RT were recruited. MMP and TIMP serum levels were analysed by immunoassay before, during and after RT. Our pilot study showed a slight increase in the levels of most MMP and TIMP with RT. However, RT produced a significantly decrease in TIMP‐1 and TIMP‐3 levels. Significant correlations were found between MMP‐3 and TIMP‐4 levels, and some of the variables studied related to patient characteristics and tumour biology. Moreover, MMP‐9 and TIMP‐3 levels could be predictive of RT toxicity. For this reason, MMP‐3, MMP‐9, TIMP‐3 and TIMP‐4 could be used as potential prognostic and predictive biomarkers for BC patients treated with RT.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study

Olivares-Urbano

Griñán‐Lisón

Zurita

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…In order to improve the survival rate, cure rate and mortality rate of cancer patients, molecular targeted therapy and gene therapy have become popular treatment methods for cancer ( 12 ). In order to improve the therapeutic effect and patient prognosis, it is necessary to focus on understanding the mechanism of cancer formation and development, and take this information as a starting point to find new effective biomarkers and therapeutic methods to accurately predict the prognosis of patients and carry out precision treatment ( 13 ), and constantly develop new targets to develop new drugs and combination treatment strategies ( 14 ). This is of great significance for the prevention, treatment and prognosis of cancer.…”

Section: Introductionmentioning

confidence: 99%

Biological functions and therapeutic potential of SRY related high mobility group box 5 in human cancer

Xue,

Xiang,

Cai

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Cancer is a heavy human burden worldwide, with high morbidity and mortality. Identification of novel cancer diagnostic and prognostic biomarkers is important for developing cancer treatment strategies and reducing mortality. Transcription factors, including SRY associated high mobility group box (SOX) proteins, are thought to be involved in the regulation of specific biological processes. There is growing evidence that SOX transcription factors play an important role in cancer progression, including tumorigenesis, changes in the tumor microenvironment, and metastasis. SOX5 is a member of SOX Group D of Sox family. SOX5 is expressed in various tissues of human body and participates in various physiological and pathological processes and various cellular processes. However, the abnormal expression of SOX5 is associated with cancer of various systems, and the abnormal expression of SOX5 acts as a tumor promoter to promote cancer cell viability, proliferation, invasion, migration and EMT through multiple mechanisms. In addition, the expression pattern of SOX5 is closely related to cancer type, stage and adverse clinical outcome. Therefore, SOX5 is considered as a potential biomarker for cancer diagnosis and prognosis. In this review, the expression of SOX5 in various human cancers, the mechanism of action and potential clinical significance of SOX5 in tumor, and the therapeutic significance of Sox5 targeting in cancer were reviewed. In order to provide a new theoretical basis for cancer clinical molecular diagnosis, molecular targeted therapy and scientific research.

show abstract

“…Matrix metalloproteinases (MMPs) play an important role in tumour metastasis by degrading extracellular matrix (ECM) components, to be specific, they allow cells to pass through ECM to reach distant targets and their expressions and activations could lead to an increase in cancer cells in almost all people (Forget et al 1999;Curran et al 2004). Among them, MMP-2 and MMP-9 have been regarded as taking primarily responsibility for basement membrane and pericellular ECM rearrangement (Di Cara et al 2018).…”

Section: Introductionmentioning

confidence: 99%

Resveratrol inhibits ACHN cells via regulation of histone acetylation

Dai

Chen

Wang

et al. 2020

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: The relationship between resveratrol and histone acetylation in renal cell carcinoma (RCC) has not yet been reported. Objective: To explore the functional role of resveratrol in RCC. Materials and methods: Functional experiments were performed to determine proliferatio n of ACHN cells with treatment of resveratrol (0, 7.8125, 15.625, 31.25 and 62.5 lg/mL, for 12, 24 and 48 h of culture) or 0.1 lM SAHA. The enzyme activities of MMP-2/-9 were measured by gelatine zymography and histone acetylation by Western blot. Results: When the cells were treated with 15.625, 31.25 and 62.5 lg/mL resveratrol, ACHN cells viability was 73.2 ± 3.5%, 61.4 ± 3.1%, 50.2 ± 4.7% for 12 h, 62.7 ± 4.5%, 52.4 ± 5.5%, 40.2 ± 3.8% for 24 h, and 60.8 ± 3.7%, 39.4 ± 5.1%, 37.6 ± 2.7% for 48 h, and the wound closure (%) of migration was increased from 0.6 to 0.7, 0.85, 0.9 for 12 h and from 0.23 to 0.3, 0.48, 0.59 for 24 h. The invasion rate was 8.5 ± 0.9%, 7.4 ± 0.3% and 5.8 ± 0.6%, and cell cycle was arrested at G1 from 42.5 ± 2.9% to 55.3 ± 5.7%, 59.8 ± 3.4%, 68.7 ± 4.6%. MMP-2/-9 expression (p < 0.05) was inhibited by resveratrol. The protein levels of histone acetylation (p < 0.01) was increased by resveratrol. Discussion and conclusions: Our results suggest that these effects might be related to a high level of histone acetylation, and resveratrol can be considered as an alternative treatment for RCC.

show abstract

New Insights into the Occurrence of Matrix Metalloproteases -2 and -9 in a Cohort of Breast Cancer Patients and Proteomic Correlations

Cited by 4 publications

References 56 publications

Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study

Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study

Biological functions and therapeutic potential of SRY related high mobility group box 5 in human cancer

Resveratrol inhibits ACHN cells via regulation of histone acetylation

Contact Info

Product

Resources

About